Cyclophosphamide, adriamycin, and DTIC polychemotherapy in advanced small cell lung cancer.
D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012075:Remission, Spontaneous; D013997:Time Factors; D014226:Triazenes / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D014226:Triazenes; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide